Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01353079 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy
A Phase 3 study, sponsored by Greer Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 429
- Enrollment target
NCT01353079 is a Phase 3 study that has completed, run by Greer Laboratories. The registered enrollment target is 429 participants.
The verdict
NCT01353079, a Phase 3 study, has completed, sponsored by Greer Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 429 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate that SLIT administered pre-and co-seasonally is effective in reducing rhinoconjunctivitis symptoms during the entire short ragweed pollen season.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Short Ragweed Pollen Allergenic Extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 429 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01353079
The ClinicalTrials.gov registry entry for NCT01353079 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 429 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Greer Laboratories, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01353079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01353079 about?
NCT01353079 is a clinical study titled "Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy". The primary objective of this study is to demonstrate that SLIT administered pre-and co-seasonally is effective in reducing rhinoconjunctivitis symptoms during the entire short ragweed pollen season.
What is the current status of trial NCT01353079?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 429 participants. The study started on 2011-04. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01353079?
The interventions under investigation include: Placebo (BIOLOGICAL), Short Ragweed Pollen Allergenic Extract (BIOLOGICAL).
Who is sponsoring clinical trial NCT01353079?
This trial is sponsored by Greer Laboratories, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.